Connect with us

Hi, what are you looking for?

Stock

Biogen CEO sees no burning need for more acquisitions

By Deena Beasley

SAN FRANCISCO (Reuters) – Biogen (NASDAQ:BIIB) expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company’s CEO said.

“The view out there in the analyst community is that the future of Biogen depends on the next deal that we do and that’s not a view that we share inside Biogen,” CEO Chris Viehbacher told Reuters in an interview on Monday during the annual JP Morgan Healthcare Conference in San Francisco.

Last Friday, Biogen offered to buy Sage Therapeutics, its marketing partner on a drug to treat postpartum depression. Sage saw its share price fall around 76% last year after a series of clinical setbacks.

Viehbacher declined to comment on the transaction, citing legal restrictions.

Shares of Biogen have dropped about 42% over the last year.

“While the deal may make financial sense for Biogen, we think it does little to change the narrative around the company, and additional revenue-generating deals are needed to change the company’s growth profile,” BMO Capital Markets analyst Evan Seigerman said in a research note.

Viehbacher said Biogen as “gained conviction” on the strength of its current pipeline, including amyloid-targeting Alzheimer’s drug Leqembi and BIIB080, an experimental drug that targets tau, a different protein found in the brains of Alzheimer’s patients.

“We are doubling down in Alzheimer’s,” the CEO said, noting that news is expected this year on an FDA filing for subcutaneous Leqembi and use of the drug as maintenance therapy.

He acknowledged that Leqembi sales have not lived up to the loftiest expectations, but said the trajectory is solid and the company is shifting its marketing strategy to target newly-diagnosed patients.

Viehbacher said Biogen also has late-stage studies underway with felzartamab in rare immune-related indications including kidney transplant patients and for experimental lupus drugs.

“It is hard to find assets worth paying for … there is still an expectation of some pretty high premiums in the market,” he said.

The CEO said Biogen has “teams of people” at the healthcare conference this week. At last year’s meeting, those teams looked at 100 companies and ended up doing two deals: a collaboration to explore molecular glue degraders with Neomorph and the acquisition of Human Immunology Biosciences.

This post appeared first on investing.com

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    You May Also Like

    Investing

    Newmont (NYSE: NEM) reported mixed financial results even as the price of gold approached its all-time high. In all, the company’s earnings per share...

    Investing

    Fisker (NYSE: FSR) stock price has been one of the best-performing electric vehicle (EV) stocks this week even as Tesla slumped. The shares jumped...

    Investing

    The Fox Corporation (NASDAQ: FOX) stock price has been under pressure as investors come to terms with the abrupt firing of Tucker Carlson. The...

    Investing

    NatWest (LON: NWG) share price rose sharply, helped by the strong results from Barclays. The stock jumped to a high of 274.8p, which was...




    Disclaimer: Oldamericanbroker.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the-company.


    Copyright © 2025 Oldamericanbroker.com